Business Wire

U.S. Companies Subjected to New Activist Campaigns Increased by 10.6% in 2022, According to Diligent

Share

Last year, companies subjected to new activist campaigns increased by 10.6% in the U.S. and 6% globally in 2022, according to a new report released today by Diligent, the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG. The Shareholder Activism Annual Review 2023 report, produced by Insightia (a Diligent brand) shows that activism flourished in 2022 with the number of campaigns returning to pre-pandemic levels, spurred on by the introduction of the universal proxy.

The rising number of campaigns underscores the need for leaders to have a 360-view of data across their organization, strengthening their ability to identify which red flags to escalate to the board, monitor and mitigate evolving risks, and document compliance and risk management efforts in defensible, auditable detail.

“Amid heightened focus on a company’s bottom line, it is increasingly important for leaders to address and mitigate the ever-evolving risks of shareholder activism,” said Josh Black, editor-in-chief at Diligent. “Complete visibility into organizational data is the first step to building such a program and reducing vulnerability to investor, shareholder, and legal action.”

Among the report’s top findings:

The U.S. and Japan drove activity, with a focus on capital allocation, board changes, and ESG

  • In the U.S., 511 companies faced activist demands, a 10.6% increase from 2021. This is in part due to the universal proxy rules, which have sent a jolt through the industry as advisers try to model how the greater choice available to investors will influence voting decisions.
  • Japan proved especially attractive to activists, thanks to an increasing number of domestic investors looking to capitalize on undervalued companies. In 2022, 108 companies faced demands, almost double the 67 and 66 companies targeted throughout 2020 and 2021, respectively.

Investors’ expectations on executive compensation continue to increase

  • Amid tightening markets and global interest rate rises, pay for performance compensation is becoming a regular part of investor engagements, with 114 companies facing remuneration demands globally throughout 2022, compared to 86 and 92 throughout 2020 and 2021, respectively.
  • 1,397 Russell 3000 CEOs received pay increases of between 1-250% from FY2020 and FY2021, with average CEO pay exceeding $22.5 million. Pay revolts are also on the rise, with average support for S&P 500 advisory “say on pay” plans reaching an eight-year low of 87.5% in 2022.

ESG activism is facing a crisis of confidence

  • Only 11.5% of environmental demands were at least partially successful in 2022, compared to 25.8% a year prior.
  • With green stocks underperforming and oil and gas prices soaring, ESG campaigns that failed to make a compelling link between a company’s financial performance and ESG credentials were doomed to fail.

The Shareholder Activism Annual Review, produced in association with Olshan Frome Wolosky, Morrow Sodali, and Alliance Advisors, is Insightia’s flagship report for data on shareholder engagement, corporate governance, and compensation.

To download the full report click here, or to view our archive of publications, visit the resource center section on the Insightia website.

About the Report

Data from Insightia’s Activism, Shorts, Voting, and Vulnerability modules run from January 1 to December 31, 2022. Compensation data runs from June 1, 2021, to May 31, 2022. Further data is available on request. For more information, please email insightia.info@diligent.com.

About Insightia

Insightia, a Diligent brand since January 2022, is a leading SaaS provider of expert insights and intelligent analytics with a focus on shareholder activism, proxy voting and corporate governance. Through its web application, Insightia One, clients can access the most complete solution for listed company intelligence on the market, with broader and deeper insights than ever before.

About Diligent

Diligent is the global leader in modern governance, providing SaaS solutions across governance, risk, compliance, audit and ESG. Empowering more than 1 million users and 700,000 board members with a holistic view of their organization’s GRC practices so they can make better decisions, faster. No matter the challenge. Learn more at diligent.com.

Follow Diligent on LinkedIn, Twitter, and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Julia Hanbury
Senior Marketing Communications Manager, Diligent
+1 778-822-6411
Jhanbury@diligent.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me

SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which

Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release

Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado

Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release

3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad

Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release

NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye